PIRSのニュース
Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference 2023/06/02 20:38:00 Finanz Nachrichten
BOSTON, MA / ACCESSWIRE / June 2, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® techno…
Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference 2023/06/02 20:30:00 Wallstreet:Online
BOSTON, MA / ACCESSWIRE / June 2, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory and cancer diseases, …
Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference 2023/05/22 12:02:00 Finanz Nachrichten
BOSTON, MA / ACCESSWIRE / May 22, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® techno…
Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference 2023/05/22 12:00:00 Wallstreet:Online
BOSTON, MA / ACCESSWIRE / May 22, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and …
Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference 2023/05/21 12:14:00 Finanz Nachrichten
BOSTON, MA / ACCESSWIRE / May 21, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® techno…
Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference 2022/09/08 20:01:00 Wallstreet:Online
BOSTON, MA / ACCESSWIRE / September 8, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer …
Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS 2022/08/24 12:08:00 Finanz Nachrichten
BOSTON, MA / ACCESSWIRE / August 24, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® tec…
Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS 2022/08/24 12:00:00 Wallstreet:Online
BOSTON, MA / ACCESSWIRE / August 24, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, …
Pieris Pharmaceuticals''s Return On Capital Employed Insights 2022/08/19 14:18:19 Benzinga
Benzinga Pro data, Pieris Pharmaceuticals (NASDAQ: PIRS ) reported Q2 sales of $3.70 million. Earnings fell to a loss of $10.34 million, resulting in a 102.67% decrease from last quarter. Pieris Pharmaceuticals collected $10.99 million in revenue during Q1, but reported earnings showed a $5.10 million loss. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign … Full story available on Benzinga.com
Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q2 2022 Results - Earnings Call Transcript 2022/08/06 21:14:03 Seeking Alpha
Pieris Pharmaceuticals, Inc. (NASDAQ:NASDAQ:PIRS) Q2 2022 Results Conference Call August 04, 2022 08:00 AM ET Company Participants Tom Bures - Chief Financial Officer Steve Yoder -…
Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference 2022/09/08 20:01:00 Wallstreet:Online
BOSTON, MA / ACCESSWIRE / September 8, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer …
Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS 2022/08/24 12:08:00 Finanz Nachrichten
BOSTON, MA / ACCESSWIRE / August 24, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® tec…
Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS 2022/08/24 12:00:00 Wallstreet:Online
BOSTON, MA / ACCESSWIRE / August 24, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, …
Pieris Pharmaceuticals''s Return On Capital Employed Insights 2022/08/19 14:18:19 Benzinga
Benzinga Pro data, Pieris Pharmaceuticals (NASDAQ: PIRS ) reported Q2 sales of $3.70 million. Earnings fell to a loss of $10.34 million, resulting in a 102.67% decrease from last quarter. Pieris Pharmaceuticals collected $10.99 million in revenue during Q1, but reported earnings showed a $5.10 million loss. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign … Full story available on Benzinga.com
Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q2 2022 Results - Earnings Call Transcript 2022/08/06 21:14:03 Seeking Alpha
Pieris Pharmaceuticals, Inc. (NASDAQ:NASDAQ:PIRS) Q2 2022 Results Conference Call August 04, 2022 08:00 AM ET Company Participants Tom Bures - Chief Financial Officer Steve Yoder -…